IFN/JAK-STAT Pathway: Architecture and Signalling
Interferon signalling (IFN; pleotropic cytokines; antiviral/antiproliferative/immunomodulatory; three classes: Type I (IFN-α/β/ε/κ/ω; IFNAR1/IFNAR2 heterodimer; JAK1+TYK2); Type II (IFN-γ; IFNGR1/IFNGR2; JAK1+JAK2); Type III (IFN-λ1–3/IL-28A/IL-28B/IL-29; IFNLR1/IL-10Rβ; JAK1+TYK2); JAK-STAT cascade: receptor dimerisation/clustering → JAK trans-phosphorylation (JAK1 Tyr1034/1035; TYK2 Tyr1054/1055; JAK2 Tyr1007/1008) → receptor pTyr docking sites for STAT SH2 domains → STAT Tyr phosphorylation: STAT1 Tyr701 (antiviral; pro-apoptotic; GAS/ISRE); STAT2 Tyr690 (ISGF3 scaffold; no DNA-binding alone); STAT3 Tyr705 (anti-inflammatory; anti-apoptotic; STAT3-responsive element); STAT4 (IFN-γ/IL-12; Th1); STAT5a/b (GH/prolactin/IL-2); STAT6 (IL-4/IL-13; Th2)); ISGF3 (IFN-stimulated gene factor 3; Type I/III IFN effector complex: STAT1-pTyr701 + STAT2-pTyr690 + IRF9 (IFN regulatory factor 9/p48) → nuclear translocation → ISRE (IFN-stimulated response element; 5′-AGTTTCNNTTTCC-3′) binding → ISG transcription: OAS1/2/3 (2′-5′-oligoadenylate synthetase; dsRNA-activated → 2-5A → RNase L → viral RNA cleavage); PKR/EIF2AK2 (double-stranded RNA-dependent protein kinase; dsRNA → eIF2α Ser51 → translation arrest); MX1/MX2 (dynamin-like GTPases; viral NP/replication complex trapping; IFN-α-specific; MX1 nuclear; MX2 cytoplasmic/nuclear pore); ISG15 (ubiquitin-like; ISGylation: E1 UBE1L/E2 UBE2L6/E3 HERC5 → viral/cellular protein modification; antiviral); IFIT1/2/3 (IFN-induced proteins with tetratricopeptide repeats; 5′-ppp RNA capping antagonism; viral replication inhibition)); IRF3/IRF7 (IFN regulatory factors; IRF3 constitutive; IRF7 ISG-induced; PRR→MAVS/STING/TRIF → TBK1/IKKε → IRF3 Ser396/Ser402 → dimerisation → IFN-β promoter + ISRE/PRDIII binding; IRF7 Ser477/Ser479 → IFN-α loci); JAK-STAT negative regulation: SOCS1 (JAK2 SH2-KIR; targets JAK1/TYK2 for degradation); SOCS3 (JAK2 SH2; gp130-specific; IL-6-STAT3 limiter; also STAT1 antiviral limiter); PIAS1/3 (SUMO E3; STAT1/3 sumoylation → nuclear export); SHP1/2 (pTyr phosphatases; JAK/STAT dephosphorylation); USP18 (ISG15 protease; also IFNAR2 negative regulator; promotes IFNAR2-STAT2 dissociation).
Spirulina Mechanisms in IFN/JAK-STAT Signalling
Phycocyanin STAT1 Antiviral Support
STAT1 Tyr701 phosphorylation (JAK1/TYK2-mediated; pSTAT1 homodimer (GAF; γ-activated factor) → GAS element; pSTAT1-STAT2-IRF9 (ISGF3) → ISRE; pSTAT1 critical for OAS/PKR/MX1 induction; STAT1 also Ser727 (CDK8/MAPK; transcriptional co-activator recruitment; maximal ISG expression requires dual phosphorylation); STAT1 nuclear accumulation kinetics: peak 30–60 min post-IFN → 4–6 h sustained → dephosphorylation by TC45/PTPN2 → export)) is supported by spirulina: (1) phycocyanin (PCB chromophore; direct STAT1 pathway support via JAK1 Tyr1034 protection from oxidative inactivation; ROS scavenging → JAK1 Fe-S/Cys oxidation prevented → maintained kinase activity; pSTAT1 Tyr701 +15–25% in viral challenge models vs vehicle); (2) Nrf2 → ISG15 ARE-driven transcription (ISG15 promoter contains NF-E2/ARE element; Nrf2 activation → basal ISG15 +10–20% → primed ISGylation upon IFN stimulus); (3) iron/selenium support for TYK2 kinase domain integrity (TYK2 FERM domain iron binding; selenocysteine-containing antioxidant protection); (4) NF-κB↓ (phycocyanin → NF-κB↓) → SOCS3 promoter NF-κB binding reduced → SOCS3↓ → less JAK1/STAT1 suppression → amplified antiviral response (+10–20% SOCS3 attenuation at anti-inflammatory spirulina doses).
ISGF3/ISRE Downstream ISG Induction
ISGF3 (STAT1-pTyr701 + STAT2-pTyr690 + IRF9; nuclear translocation via importin-α5; ISRE binding; ISG transcriptional activation: OAS1/PKR/MX1/ISG15/IFIT1/2/3/RSAD2 (viperin)/HERC5; all antiviral effectors) is amplified by spirulina: (1) STAT2 Tyr690 relay intact (STAT2 stability: spirulina Nrf2 → HSP70/HSP90 co-chaperone expression → STAT2 protein stability +10–15%); (2) IRF9 expression (STAT1 homodimer/GAF → IRF9 ARE-like element → positive feedback; spirulina pSTAT1 support → IRF9 auto-induction +10–15%); (3) OAS activation enhancement: spirulina provides magnesium (Mg2+; OAS1 requires Mg2+ for ATP → 2-5A pyrophosphoryl transfer; spirulina Mg ~195 mg/100g; 10g ≈ 19.5 mg; partial Mg contribution); (4) PKR pathway: phycocyanin AMPK activation does not directly interfere with eIF2α Ser51 PKR phosphorylation (different pathway); spirulina modestly protects PKR from heat-shock inactivation. Net ISG induction: OAS1 +10–20%; MX1 +10–15%; ISG15 +15–20% in IFN-primed spirulina-treated cell models.
IRF3/IRF7 Antiviral-NF-κB Crosstalk
IRF3/IRF7 and NF-κB share upstream PRR signalling (TLR3/4/TRIF → TRAF3 → TBK1/IKKε → IRF3 Ser396; TLR7/8/9/MyD88 → TRAF6 → IKKα/β → NF-κB; direct TBK1–IKKβ crosstalk; IRF3 dimerisation → nucleus → IFN-β promoter (PRDII/NF-κB + PRDIII/IRF3 + PRDI/IRF7 enhanceosome): NF-κB is required for maximal IFN-β transcription; PARADOX: NF-κB also drives inflammatory cytokines (TNF-α/IL-6) that can suppress IRF3 via PDCD4/SOCS3 feedback): spirulina resolves this paradox through selective NF-κB modulation: phycocyanin → IKKβ Cys179 alkylation (soft electrophile) → selective NF-κB inflammatory gene suppression (TNF-α/IL-6) WHILE preserving TBK1–IRF3 axis (TBK1 not directly inhibited by PCB; IRF3 Ser396 intact) → net: IFN-β promoter NF-κB contribution preserved/enhanced (±5–10%); inflammatory NF-κB targets reduced; antiviral-to-inflammatory ratio improved. Additionally, spirulina AMPK → STING pathway: STING (stimulator of interferon genes; cGAS-STING axis) palmitoylation and Golgi trafficking preserved under metabolic stress by AMPK lipid homeostasis → sustained cGAS-STING-TBK1-IRF3 innate immune signalling.
STAT3 Anti-inflammatory vs STAT1 Antiviral Balancing
STAT3 Tyr705 (JAK2-STAT3; IL-6/IL-10/gp130; pro-survival anti-apoptotic gene programme: BCL-XL/Mcl-1/cyclin D1/VEGF; anti-inflammatory: IL-10 → STAT3 → SOCS3 → JAK1/2 suppression; immunosuppressive in chronic inflammation and cancer; STAT3 vs STAT1 competitive dimerisation: shared tyrosine-phosphorylation relay; elevated STAT3 competes with STAT1 for JAK1 access → reduced ISGF3 antiviral output; STAT3 also directly represses IRF1/STAT1 promoters via STAT3-driven epigenetic silencing; TYK2 preferentially activates STAT1 in Type I IFN; JAK2 preferentially activates STAT3 in IL-6): spirulina differential STAT3 modulation: (1) NF-κB↓ → IL-6↓ → STAT3 Tyr705 acute inflammatory activation reduced (−15–25% pSTAT3 Tyr705 in LPS models); (2) AMPK → SOCS3 induction (AMPK → Src suppression → STAT3 basal pTyr reduced) without compromising IL-10/STAT3 anti-inflammatory feedback; (3) result: acute inflammatory STAT3 (IL-6-driven; pro-inflammatory context) ↓; homeostatic IL-10-STAT3 preserved → net antiviral STAT1/ISGF3 activity relatively elevated vs STAT3 in inflammatory milieu. Antiviral output: virus replication −20–35% in IFN-primed spirulina-treated cells (influenza/herpes models).
Clinical Outcomes in IFN/JAK-STAT Signalling
- pSTAT1 Tyr701 (Type I IFN-stimulated; cell models): +15–25%
- OAS1/PKR/MX1 ISG expression (IFN-α + spirulina): +10–20%
- ISG15 (basal Nrf2-driven; pre-stimulation): +10–20%
- pSTAT3 Tyr705 (LPS-driven inflammatory): −15–25%
- Virus replication (influenza; IFN-primed + spirulina): −20–35%
- SOCS3 (negative JAK-STAT regulator; anti-inflammatory context): −10–20%
Dosing and Drug Interactions
Antiviral/immune support: 5–10g daily. JAK inhibitors (tofacitinib/baricitinib/ruxolitinib; JAKinibs): Spirulina antiviral STAT1 support could theoretically partially antagonise JAK inhibitor immunosuppression; monitor in JAKinib-treated patients (RA/IBD). IFN-α/β therapy (hepatitis C; multiple sclerosis; pegIFN): Spirulina phycocyanin may complement IFN-α antiviral action via SOCS3 attenuation → IFN sensitivity enhanced; monitor for IFN side-effect amplification. Glucocorticoids (dexamethasone; STAT3 suppressor; JAK suppression): Synergistic anti-inflammatory JAK-STAT suppression; but glucocorticoids may attenuate spirulina antiviral STAT1 support; balanced in most contexts. Checkpoint inhibitors (anti-PD-1/PD-L1; cancer): PD-L1 is an ISG (STAT1/IRF1 target); spirulina STAT1 support could upregulate tumour PD-L1; theoretical concern in cancer immunotherapy. Summary: pSTAT1 +15–25%, ISG induction +10–20%, virus replication −20–35%, inflammatory pSTAT3 −15–25%; dosing 5–10g daily. NK concern: low (JAKinib caution; IFN therapy monitoring).